Metastatic-directed therapy using PSMA-PET/CT at PSA relapse

Oscar Lilleby; Eivor Hernes; Wolfgang Lilleby

doi:10.1016/j.eucr.2019.100992

Metastatic-directed therapy using PSMA-PET/CT at PSA relapse

Urol Case Rep. 2019 Aug 9:27:100992. doi: 10.1016/j.eucr.2019.100992. eCollection 2019 Nov.

Authors

Oscar Lilleby¹, Eivor Hernes², Wolfgang Lilleby³

Affiliations

¹ University of Copenhagen, Faculty of Medicine, Copenhagen, Denmark.
² Department of Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
³ Department of Radiation Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.

Abstract

The side effects of androgen deprivation therapy (ADT) as general treatment against prostate cancer are known to impair quality of life. However, the optimal onset of ADT at PSA relapse is unknown, especially in patients with normal testosterone. In our case a limited PSMA avid lymph node was detected on PET/CT. Our case highlights the importance of metastasis-directed therapy balancing general versus tailored treatment in the decision making in the era of advanced molecular imaging. By using PSMA-PET/CT and radiation we were able to pinpoint the metastasis prolonging the ADT-free survival, thus sparing the patient the side-effects of continuous ADT.

Keywords: Metastasis-directed therapy; PSA; Prostate cancer; Recurrence.

Publication types

Case Reports